Back to Journals » Breast Cancer: Targets and Therapy » Volume 4

A triple negative breast cancer: what it is not!

Authors Katakkar S

Received 21 November 2011

Accepted for publication 6 January 2012

Published 24 February 2012 Volume 2012:4 Pages 21—23


Review by Single anonymous peer review

Peer reviewer comments 2

Suresh B Katakkar

Regional Medical Oncology Hematology Leader, Centre for the North, BC Cancer Agency, Prince George, British Columbia, Canada

Abstract: The triple negative cancer is an unusual, and at the same time, a unique entity where the discordance rate is almost 18%. That means 18% of Her2 negative results will transform into a Her2 positive status and will have the affinity to spread to the central nervous system (CNS). With the identification of CD44, CD24, and ALDH1, we may be able to determine which group of triple negative breast cancer patients will have CNS metastasis. This case illustrates the Her2 expressing cells have higher CNS affinity. As the original tumor was Her2 negative, if a genomic assay was then done on this patient, we would have identified the potential of CNS involvement. In conclusion, genomic assays should be routinely done on triple negative cancers.

Keywords: triple negative, breast cancer, claudin high or low, genomic microassay

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]